Emergent BioSolutions News

Emergent BioSolutions Reports Surprising Q1 2024 Earnings, Exceeding Revenue and Net Income ...

Yahoo Finance06:15

Emergent BioSolutions Sees Q2 Revenue $160M-$210M Vs $244.5M Est.; Updates FY24 Revenue From $900M-$1B To $1B-$1.1B Vs $1.02B Est.

2024 FINANCIAL FORECASTThe Company provides the following updated financial forecast for full year 2024 and initial forecast for Q2 2024, in both instances reflecting management's expectations based o

Benzinga05:15

Emergent Biosolutions Shares Are Trading Higher After the Company Announced Operational Changes to Stabilize Its Financial Position and Reported Q1 Financial Results.

Emergent Biosolutions Shares Are Trading Higher After the Company Announced Operational Changes to Stabilize Its Financial Position and Reported Q1 Financial Results.

Benzinga05:13

Emergent BioSolutions Q1 Adj $0.17 May Not Compare To $(0.83) Estimate, Sales $300.40M Beat $224.50M Estimate

Emergent BioSolutions Q1 Adj $0.17 May Not Compare To $(0.83) Estimate, Sales $300.40M Beat $224.50M Estimate

Benzinga05:12

Emergent Biosolutions Adjusts Contract Terms and Preps Q1 Report

TipRanks05:03

Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q1 Revenue $300.4M, Vs. Street Est of $224.5M

04:59 PM EDT, 05/01/2024 (MT Newswires) -- Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q1 Revenue $300.4M, vs. Street Est of $224.5M

MT Newswires04:59

Emergent Biosolutions 1Q EPS 17c >EBS

Emergent Biosolutions 1Q EPS 17c >EBS

Dow Jones04:57

Emergent Biosolutions 1Q Rev $300.4M >EBS

Emergent Biosolutions 1Q Rev $300.4M >EBS

Dow Jones04:57

Press Release: Emergent BioSolutions Reports First Quarter 2024 Financial Results

Emergent BioSolutions Reports First Quarter 2024 Financial Results -- First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance range -- First Quarter 2024 Net Income

Dow Jones04:57

Narcan-Maker Emergent BioSolutions to Cut 300 Jobs, Close Facilities

By Paul Ziobro Emergent BioSolutions is closing several manufacturing facilities and cutting hundreds of jobs as part of a restructuring as the company narrows its focus on products, including Narcan

WSJ04:56

Emergent Biosolutions: As Part of the Operational Changes, Emergent Will Shut Dn Baltimore-Bayview Drug Substance Manufacturing Facility and Rockville, Md., Drug Pdt Facility >EBS

Emergent Biosolutions: As Part of the Operational Changes, Emergent Will Shut Dn Baltimore-Bayview Drug Substance Manufacturing Facility and Rockville, Md., Drug Pdt Facility >EBS

Dow Jones04:20

Emergent Biosolutions: Will Continue to Focus on Core Products Business, Medical Countermeasures and NARCAN Nasal Spray >EBS

Emergent Biosolutions: Will Continue to Focus on Core Products Business, Medical Countermeasures and NARCAN Nasal Spray >EBS

Dow Jones04:20

Emergent Biosolutions: Will Concentrate Ops at Sites in Winnipeg, Canada, and Lansing, Mich., While the Co Actively Explores Strategic Alternatives for Other Sites Throughout Yr >EBS

Emergent Biosolutions: Will Concentrate Ops at Sites in Winnipeg, Canada, and Lansing, Mich., While the Co Actively Explores Strategic Alternatives for Other Sites Throughout Yr >EBS

Dow Jones04:20

Emergent Biosolutions: Actions Will Lead to a Reduction of Approximately 300 Employees Across All Areas of the Co, and the Elimination of Approximately 85 Positions That Are Currently Vacant >EBS

Emergent Biosolutions: Actions Will Lead to a Reduction of Approximately 300 Employees Across All Areas of the Co, and the Elimination of Approximately 85 Positions That Are Currently Vacant >EBS

Dow Jones04:20

Emergent Biosolutions: Reorganization Will Align With Evolving Business Goals, Strategic Priorities and New Operational Plan >EBS

Emergent Biosolutions: Reorganization Will Align With Evolving Business Goals, Strategic Priorities and New Operational Plan >EBS

Dow Jones04:16

Emergent Biosolutions: Overall Efforts Expected to Deliver Annual Cost Savings of Approximately $80M >EBS

Emergent Biosolutions: Overall Efforts Expected to Deliver Annual Cost Savings of Approximately $80M >EBS

Dow Jones04:16

Press Release: Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position -- Proactive changes aim to ensure long-term sustainability and growth, optimize operations, str

Dow Jones04:10

Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone

Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment to be easily accessible in case of an emergency GAITHERSBURG,

GlobeNewswireMay 1 23:03

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

GainersAkanda (NASDAQ:AKAN) shares moved upwards by 69.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. NanoVibronix (NASDAQ:NAOV) shares moved upwar

BenzingaMay 1 20:06

Emergent BioSolutions Announces Amendment to Its Existing Credit Facility

GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has entered into a "Consent, Waiver and Seventh Amendment" to its existing credit facility. "In light of

GlobeNewswireMay 1 05:26